Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘Made In China’ Provision Removed From Green Channel Policy

This article was originally published in The Gray Sheet

Executive Summary

The original draft of an accelerated approval policy in China for innovative devices included a condition that a product being considered for the special pathway “is produced in China.” That condition has been removed from the latest draft following pressure from the U.S. government.

You may also be interested in...



Global View: Talking Harmonization And China With Jeffrey Gren

The just-retired Commerce official Jeffrey Gren discusses the impact of globalization on the medical device industry, and the issues the sector is facing in China.

New China Fast-track Review Allows International Devices Accelerated Approval

China FDA revised its regulation allowing both domestic and foreign device makers to apply for the special review process. However, a murky domestically initiated innovation requirement still worries multinational companies.

Global View: Talking Harmonization And China With Jeffrey Gren

The just-retired Commerce official Jeffrey Gren discusses the impact of globalization on the medical device industry, and the issues the sector is facing in China, in an interview with “The Gray Sheet.” Gren retired from the U.S. Department of Commerce in January after decades of focusing on device and drug trade issues.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032393

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel